Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of "Buy" from Analysts

Key Points

• Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has received a consensus rating of "Buy" from seven analysts, with an average target price of $53.00 for the next twelve months.
• Institutional investors currently hold 47.53% of the company's stock, with several large firms increasing their positions recently.
• The company reported a loss of $0.88 per share in its latest earnings results, which was below analysts' expectations, amidst very low revenue of just $0.19 million.

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) have been assigned an average recommendation of "Buy" from the seven brokerages that are currently covering the firm, MarketBeat.com reports. Seven research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokers that have covered the stock in the last year is $53.00.

DNTH has been the subject of several recent research reports. HC Wainwright reiterated a "buy" rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research note on Tuesday, May 13th. Robert W. Baird reduced their price objective on Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating for the company in a research note on Tuesday, May 13th. Finally, William Blair began coverage on Dianthus Therapeutics in a research note on Wednesday, July 2nd. They issued an "outperform" rating on the stock.

Dianthus Therapeutics Price Performance

Shares of DNTH traded up $0.54 during mid-day trading on Friday, reaching $20.44. 26,699 shares of the company's stock were exchanged, compared to its average volume of 318,052. The business's fifty day simple moving average is $19.37 and its 200-day simple moving average is $20.01. The stock has a market capitalization of $657.92 million, a PE ratio of -6.29 and a beta of 1.43. Dianthus Therapeutics has a 52-week low of $13.36 and a 52-week high of $32.27.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.02). Dianthus Therapeutics had a negative return on equity of 34.72% and a negative net margin of 2,364.56%. The business had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.87 million. Equities research analysts predict that Dianthus Therapeutics will post -2.61 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. American Century Companies Inc. boosted its holdings in Dianthus Therapeutics by 3.8% in the 4th quarter. American Century Companies Inc. now owns 43,996 shares of the company's stock valued at $959,000 after purchasing an additional 1,629 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of Dianthus Therapeutics in the 4th quarter valued at approximately $33,000. JPMorgan Chase & Co. lifted its holdings in shares of Dianthus Therapeutics by 14.0% in the 4th quarter. JPMorgan Chase & Co. now owns 12,129 shares of the company's stock valued at $264,000 after buying an additional 1,490 shares during the period. Wellington Management Group LLP boosted its stake in shares of Dianthus Therapeutics by 12.2% in the fourth quarter. Wellington Management Group LLP now owns 60,337 shares of the company's stock valued at $1,315,000 after buying an additional 6,552 shares in the last quarter. Finally, FMR LLC grew its holdings in Dianthus Therapeutics by 0.8% during the fourth quarter. FMR LLC now owns 4,439,281 shares of the company's stock worth $96,776,000 after acquiring an additional 36,133 shares during the period. 47.53% of the stock is currently owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.